Endomembrane targeting of human OAS1 p46 augments antiviral activity
Frank Soveg(University of Washington), Ram Savan(University of Washington), Tien-Ying Hsiang(University of Washington), Jane H. Buckner(Benaroya Research Institute), Adriana Forero(University of Washington), J. Kenneth Baillie(NHS Lothian), Michael Gale(University of Washington), Eileen T. McAnarney(Texas Medical Center), Eric J. Allenspach(University of Washington), Amy E.L. Stone(University of Colorado Denver), Nandan S. Gokhale(University of Washington), Karen Cerosaletti(Virginia Mason Medical Center), Shivam A. Zaver(University of Pennsylvania), Alison M. Kell(University of New Mexico), Saumendra N. Sarkar(University of Pittsburgh), Daniel B. Stetson(University of Washington), Chiraag Balu(University of Washington), Vineet D. Menachery(Emory University), Justin A. Roby(Charles Sturt University), Uma Malhotra(Virginia Mason Medical Center), Joseph Pérez(UPMC Hillman Cancer Center), Joshua J. Woodward(University of Washington), Snehal Ozarkar(University of Washington), Katharina Esser‐Nobis(University of Washington), Cate Speake(Benaroya Research Institute), Johannes Schwerk(Helmholtz Centre for Infection Research), Erola Pairo‐Castineira(Roslin Institute), Jonathan M. Clingan(University of Washington), Julian R. Smith(University of Washington), Jennifer Hyde(University of Washington)
Cited by 80
Related Papers
An atlas of active enhancers across human cell types and tissues
|Nature|2014|2.8k
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k